Cargando…
Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits
Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies. A retrospective analysis was performed of women who received platinum/bevacizumab (PB) chemotherapy...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720391/ https://www.ncbi.nlm.nih.gov/pubmed/29234709 http://dx.doi.org/10.1016/j.gore.2017.09.003 |